



Pitney Pharmaceuticals
Pty Limited



Investor Webinar

14 March 2023 – Perth, Australia: PharmAust Limited (ASX: PAA & PAAO), a clinical-stage biotechnology company, is pleased to advise shareholders and investors that the Company will be presenting as part of the free Broker Briefing Biotech & Nutrition Investor Webinar on Thursday 16 March 2023.

Date: 16 March 2023

Time: 11:30am AEDT / 8:30am AWST

Presenter: Executive Chairman, Dr Roger Aston, presenting at 12:00pm AEDT / 9:00am AWST

The Company invites shareholders, investors, and media to participate in this digital event by registering online via the link below:

https://us06web.zoom.us/webinar/register/1716606999117/WN_Hwj9PbRTRE2qtdPZ0rtPSA

Participants will be able to submit questions via the panel throughout the presentation, however, we encourage shareholders and investors to send through questions via email beforehand info@brokerbriefing.com

This announcement has been approved for release to ASX by the Board of Directors.

Enquiries:

Anusha Aubert
Investor Relations
investorenquiries@pharmaust.com

P +61 (8) 9202 6814

F +61 (8) 9467 6111

W www.pharmaust.com



About PharmAust Limited:

PharmAust Limited is listed on the Australian Securities Exchange (PAA) and the Frankfurt Stock Exchange (ECQ). PAA is a clinical-stage company developing therapeutics for both humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development. These efforts are supported by PAA's subsidiary, Epichem, a highly successful contract medicinal chemistry company that generated \$3.4 million in sales of goods & services in FY 2022.

PAA's lead drug candidate is monepantel (MPL), a novel, a potent and safe inhibitor of the mTOR pathway – a pathway having key influences in cancer growth and neurodegenerative diseases. MPL has been evaluated in Phase 1 clinical trials in humans and Phase 2 clinical trials in dogs. MPL treatment was well-tolerated in humans, demonstrating preliminary evidence of anticancer activity. MPL showed objective anticancer activity in dogs. PAA is uniquely positioned to commercialise MPL for treating human and veterinary cancers and neurodegenerative diseases as it advances a reformulated version of this drug through Phase 1 and 2 clinical trials.